Articles from Cencora

Cencora, Inc. (NYSECOR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025.

Cencora, Inc. (NYSECOR) today announced the completion of its previously announced acquisition of Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists.

Cencora, Inc. (NYSECOR) today announced the closing of its public offering of $500,000,000 aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”), $600,000,000 aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the “2029 Notes”) and $700,000,000 aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2029 Notes, the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024.

Cencora, a global healthcare company, announced the launch of Accelerate Pharmacy Solutions, a unified portfolio of solutions designed to help hospital and health systems customers optimize operations and improve financial performance.

Cencora, Inc. (NYSECOR) today announced that it priced $500 million aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”), $600 million aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the “2029 Notes”) and $700 million aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2029 Notes, the “Notes”), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024. The offering is expected to close on December 9, 2024, subject to the satisfaction of customary closing conditions. Cencora intends to use the net proceeds from the offering to finance the acquisition of the majority of Retina Consultants of America and related fees and expenses, and for general corporate purposes.

Cencora, a global healthcare company, will host its inaugural Product Showcase, an event that will provide increased visibility into the company’s portfolio of solutions and the products it’s developing to support the evolving needs of its customers.

Cencora, Inc. (NYSECOR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $0.02 for the September quarter of fiscal 2024, compared to $1.72 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 16.8 percent to $3.34 in the fiscal fourth quarter. For fiscal year 2024, diluted EPS decreased 11.7 percent to $7.53. For fiscal year 2024, adjusted diluted EPS increased 14.8 percent to $13.76.

Cencora, Inc. (NYSECOR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists, from Webster Equity Partners.

Cencora, Inc. (NYSECOR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora’s enterprise leadership team, bringing their extensive experience and expertise to help advance the company’s pharmaceutical-centric strategy and drive growth for Cencora and its customers.

Cencora, Inc. (NYSECOR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 6, 2024.

Cencora (formerly AmerisourceBergen), a global healthcare company, announced its two latest pharmacy education initiatives that are designed to equip health system pharmacy residents with knowledge of the pharmacy supply chain and wholesale distribution, as well as its connectivity to patient care services. Cencora launched the first of these initiatives, a 12-month Pharmacy Supply Chain Residency Forum, on July 1. The organization will also launch its Combined PGY1/PGY2 Corporate Pharmacy Administration and Leadership (CPAL) with Masters Residency Programs in the summer of 2025.

Cencora, Inc. (NYSECOR) today announced that its Board of Directors has elected Frank Clyburn as a new independent director, effective October 1, 2024. With the election of Mr. Clyburn, the Board of Directors will increase to thirteen members.

Alcura, a provider of specialized clinical trial services and a part of Cencora, has been granted a Manufacturing and Importation Authorization (MIA) license for cell and gene therapies (CGT) by the Spanish Agency of Medicines and Medical Devices. The certification, coupled with Alcura’s cryogenic storage capacity and team of experts, enables the company to provide enhanced support to developers planning to bring investigational or commercially approved CGTs into Europe.

Cencora, Inc. (NYSECOR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.

Good Neighbor Pharmacy (GNP), a national franchise for independent pharmacies offered through Cencora, announced that it has been ranked “#1 in Customer Satisfaction with Chain Drug Store Pharmacies” in the J.D. Power 2024 U.S. Pharmacy StudySM. This is the 13th time that Good Neighbor Pharmacy has earned this recognition in the last 15 years and marks the network’s eighth consecutive win.

Cencora, Inc. (NYSECOR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.42 for the third quarter of fiscal 2024 compared to $2.35 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 14.4 percent to $3.34 in the fiscal third quarter from $2.92 in the prior year third quarter.

Good Neighbor Pharmacy, a national independent pharmacy network offered through Cencora, convened more than 3,500 independent pharmacy owners and other partners to celebrate its annual marquee tradeshow and conference, ThoughtSpot. Now in its 13th year, ThoughtSpot celebrates the Good Neighbor Pharmacy network and its pharmacists’ enduring dedication to improving the health and wellness of their communities, while paving the path of independent pharmacy forward.

Cencora, Inc. (NYSECOR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 31, 2024.

Cencora, Inc. (NYSECOR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $400 million in a private transaction.

Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene Therapy (CGT) Summit, an event designed to explore the latest developments in the CGT sector and strategies to accelerate product commercialization and patient access.

Cencora, Inc. (NYSECOR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.

Cencora, Inc. (NYSECOR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 1, 2024.

Cencora, Inc. (NYSECOR) today announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Executive Chair of the Cencora Board of Directors, effective October 1, 2024. Robert P. Mauch, PharmD, PhD, current Chief Operating Officer of Cencora, will succeed Collis as President and CEO, and will also be appointed as a member of the Company's Board, effective the same date.

With the increasing number of cell and gene therapy (CGT) products in clinical development, Cencora’s FormularyDecisions launched a new resource designed to provide healthcare payers with centralized access to information on approved therapies and products in the pipeline.

Cencora, Inc. (NYSECOR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.

Cencora, Inc. (NYSECOR) today announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 23, 2021.

Cencora (formerly AmerisourceBergen), a global healthcare company, released its 2023 Environmental, Social and Governance (ESG) Report. The report and the related ESG Reporting Index feature detailed information on Cencora’s ESG performance and its commitment to operations that benefit the planet and people more broadly. For the sixth year in a row, selected material topics and indicators contained in the report and index have been third-party verified by ERM Certification and Verification Services.

Cencora, Inc. (NYSECOR) today announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 23, 2021. The offering is expected to close on February 7, 2024, subject to the satisfaction of customary closing conditions. Cencora intends to use the net proceeds from the offering to redeem all of its 3.400% Senior Notes due May 15, 2024 (the “2024 Notes”) with any remaining net proceeds to be used for general corporate purposes.

Cencora, Inc. (NYSECOR) today reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.

Cencora, Inc. (NYSECOR) today announced that it plans to release its results for the First Quarter of Fiscal 2024 on Wednesday, January 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on January 31, 2024.

World Courier, a global specialty logistics provider and a part of Cencora (formerly AmerisourceBergen), will open transport stations in three new markets in the United States, expanding its presence and capacity to deliver specialized logistics support as the specialty pharmaceutical market continues to grow.

Cencora, Inc. (NYSECOR), formerly AmerisourceBergen Corporation, today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance’s entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended.

Cencora, Inc. (NYSECOR), formerly AmerisourceBergen Corporation, today reported that in its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion. Revenue increased 9.9 percent to $262.2 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth quarter. For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53. For fiscal year 2023, adjusted diluted EPS increased 8.7 percent to $11.99.

MWI Animal Health, a provider of state-of-the-art technology solutions and services for veterinary practices, and part of Cencora (formerly AmerisourceBergen), today announced that Shepherd Veterinary Software, which offers a veterinary practice information management software (PIMS), is now fully and seamlessly integrated with MWI’s AllyDVM client engagement platform. Shepherd users can now take advantage of AllyDVM’s expansive service offerings including robust client communications, retention and analytics tools.

Cencora, Inc. (NYSECOR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thursday, November 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 2, 2023.

Cencora, Inc. (NYSECOR) today announced the completion of its name and stock ticker change from AmerisourceBergen Corporation NYSE: ABCNYSEABC)